Glucagon Novo Nordisk

Glucagon Novo Nordisk is a prescription injectable medication that contains the hormone glucagon as its sole active ingredient. It is supplied in a sterile solution for intramuscular, intravenous, or subcutaneous administration. The product is marketed in the European Union and belongs to the hormone drug class, specifically classified as an antihypoglycemic agent used to raise blood glucose levels during severe hypoglycemia in emergency situations for patients.

Glucagon Novo Nordisk is indicated for the rapid treatment of severe hypoglycemia when oral glucose administration is not feasible.

- Acute management of insulin‑induced hypoglycemia in adults and children. - Emergency reversal of hypoglycemia in patients with diabetes mellitus. - Use when a patient is unconscious, unable to swallow, or has seizures due to low blood sugar. - Administration by trained healthcare professionals or caregivers in a crisis situation.

The safety profile of Glucagon Novo Nordisk includes both frequently observed and rare but serious adverse reactions.

Common: - Nausea or vomiting. - Flushing or warmth at the injection site. - Headache. - Transient rise in blood pressure.

Serious: - Severe allergic reaction (anaphylaxis) with rash, itching, or swelling. - Cardiac arrhythmia or palpitations. - Hypotension or shock in rare cases.

Before using Glucagon Novo Nordisk, certain precautions should be considered to ensure safe administration.

- Verify the diagnosis of severe hypoglycemia and confirm that oral glucose is not possible. - Use only with a sterile, unopened cartridge or vial; discard any product that appears discolored or contains particles. - Assess for a history of adrenal or pituitary insufficiency, as glucagon may be less effective. - Monitor cardiovascular status, especially in patients with known heart disease. - Avoid repeat dosing within 24 hours unless directed by a healthcare professional. - Keep the medication out of reach of children and store according to label instructions.

Glucagon Novo Nordisk may interact with other medicines; understanding these interactions helps prevent reduced efficacy or increased risk.

Avoid: - Beta‑blockers, which can blunt the glucose‑raising response. - Insulin or other antihyperglycemic agents given shortly before glucagon, increasing risk of rebound hyperglycemia.

Use with caution: - Catecholamine‑releasing drugs (e.g., epinephrine) that may amplify cardiovascular effects. - Oral contraceptives or hormone therapies that could affect glucose metabolism. - Certain diuretics that influence electrolyte balance.